Methotrexate in psoriasis: A systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity

Journal of the European Academy of Dermatology and Venereology

Volumn 25, Issue SUPPL. 2, 2011, Pages 12-18

  Montaudie H ^a   Sbidian, E ^b   Paul, C ^c   Maza, A ^c   Gallini, A ^d   Aractingi, S ^e   Aubin, F ^f   Bachelez, H ^b   Cribier, B ^g   Joly, P ^h   Jullien, D ⁱ   Le Maitre M ^f   Misery, L ^g   Richard, M A ^h   Ortonne, J P ^a  

^a UNIVERSITÉ CÔTE D'AZUR   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c UNIVERSITÉ DE TOULOUSE   (France)

^d INSERM   (France)

^e HÔPITAL TENON   (France)

^f UNIVERSITY HOSPITAL OF BESANÇON   (France)

^g UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^h UNIVERSITÉ DE ROUEN   (France)

ⁱ EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CYCLOSPORIN A; FOLIC ACID; FOLINIC ACID; HYDROXYUREA; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE;

ALCOHOL CONSUMPTION; CLINICAL PROTOCOL; COCHRANE LIBRARY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMBASE; ENZYME BLOOD LEVEL; FIBROSCAN; GASTROINTESTINAL SYMPTOM; HEPATITIS B; HEPATITIS C; HUMAN; INCIDENCE; LIVER FIBROSIS; LIVER TOXICITY; MEDLINE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT MONITORING; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION;

DERMATOLOGIC AGENTS; DRUG-INDUCED LIVER INJURY; HUMANS; INCIDENCE; METHOTREXATE; PSORIASIS; RISK FACTORS; TREATMENT OUTCOME;

EID: 79952552655     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.03991.x     Document Type: Review

References (32)

1. Roenigk HH Jr, Maibach HI, Weinstein GP. Methotrexate therapy for psoriasis. Guideline revisions. Arch Dermatol 1973; 108: 35.
2. Roenigk HH Jr, Auerbach R, Maibach HI et al. Methotrexate guidelines - revised. J Am Acad Dermatol 1982; 6: 145-155. Review
3. Roenigk HH, Auerbach R, Maibach HI et al. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998; 38: 478-485. (Pubitemid 28125534)
4. Kalb RE, Strober B, Weinstein G et al. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2009; 60: 824-837.
5. Paul C, Gallini A, Maza A et al. Evidence-based recommendations on conventional systemic treatments in psoriasis: systematic review and expert opinion of a panel of dermatologists. J Eur Acad Dermatol Venereol. 2011; 25(Suppl. 2): 2-11.
6. Heydendael VM, Spuls PI, Opmeer BC et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003; 349: 658-665. (Pubitemid 36975998)
7. Flytström I, Stenberg B, Svensson A et al. Methotrexate vs. cyclosporine in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial. Br J Dermatol. 2008; 158: 116-121. Epub 2007. (Pubitemid 350221914)
8. Saurat JH, Stingl G, Dubertret L, CHAMPION Study Investigators et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008; 158: 558-566. Epub 2007. (Pubitemid 351239154)
9. Akhyani M, Chams-Davatchi C, Hemami MR et al. Efficacy and safety of mycophenolate mofetil vs. methotrexate for the treatment of chronic plaque psoriasis. J Eur Acad Dermatol Venereol 2010; 24: 1447-51.
10. Ranjan N, Sharma NL, Shanker V et al. Methotrexate versus hydroxycarbamide (hydroxyurea) as a weekly dose to treat moderate-to-severe chronic plaque psoriasis: a comparative study. J Dermatolog Treat 2007; 18: 295-300. (Pubitemid 47537262)
11. Sandhu K, Kaur I, Kumar B et al. Efficacy and safety of cyclosporine versus methotrexate in severe psoriasis: a study from north India. J Dermatol 2003; 30: 458-463. (Pubitemid 36829974)
12. Chládek J, Simková M, Vanecková J et al. The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis. Eur J Clin Pharmacol 2008; 64: 347-355.
13. Salim A, Tan E, Ilchyshyn A et al. Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial. Br J Dermatol 2006; 154: 1169-1174. (Pubitemid 43727401)
14. van Ede AE, Laan RF, Rood MJ et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2001; 44: 1515-1524. (Pubitemid 32651731)
15. Braun J, Kästner P, Flaxenberg P, MC-MTX.6/RH Study Group et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 2008; 58: 73-81.
16. Weinstein GD, Goldfaden G, Frost P. Methotrexate. Mechanism of action on DNA synthesis in psoriasis. Arch Dermatol 1971; 104: 236-243.
17. Robinson JK, Baughman RD, Auerbach R et al. Methotrexate hepatotoxicity in psoriasis. Consideration of liver biopsies at regular intervals. Arch Dermatol 1980; 116: 413-415.
18. Rosenberg P, Urwitz H, Johannesson A et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol 2007; 46: 1111-1118. (Pubitemid 46669734)
19. Themido R, Loureiro M, Pecegueiro M et al. Methotrexate hepatotoxicity in psoriatic patients submitted to long-term therapy. Acta Derm Venereol 1992; 72: 361-364.
20. Zachariae H, Heickendorff L, Sogaard H. The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis: a 10-year follow-up. Br J Dermatol 2001; 143: 100-103. (Pubitemid 32154599)
21. Malatjalian DA, Ross JB, Williams CN et al. Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up. Can J Gastroenterol 1996; 10: 369-375. (Pubitemid 26364819)
22. Boffa MJ, Chalmers RJ, Haboubi NY et al. Sequential liver biopsies during long-term methotrexate treatment for psoriasis: a reappraisal. Br J Dermatol 1995; 133: 774-778.
23. Newman M, Auerbach R, Feiner H et al. The role of liver biopsies in psoriatic patients receiving long-term methotrexate treatment. Improvement in liver abnormalities after cessation of treatment. Arch Dermatol 1989; 125: 1218-1224.
24. Boffa MJ, Smith A, Chalmers RJ et al. Serum type III procollagen aminopeptide for assessing liver damage in methotrexate-treated psoriatic patients. Br J Dermatol 1996; 135: 538-544. (Pubitemid 26341933)
25. Mitchell D, Smith A, Rowan B et al. Serum type III procollagen peptide, dynamic liver function tests and hepatic fibrosis in psoriatic patients receiving methotrexate. Br J Dermatol 1990; 122: 1-7. (Pubitemid 20047028)
26. Van Dooren-Greebe RJ, Kuijpers AL, Buijs WC et al. The value of dynamic hepatic scintigraphy and serum aminoterminal propeptide of type III procollagen for early detection of methotrexate-induced hepatic damage in psoriasis patients. Br J Dermato 1996; 134: 481-487. (Pubitemid 26090943)
27. Zachariae H, Søgaard H, Heickendorff L. Serum aminoterminal propeptide of type III procollagen. A non-invasive test for liver fibrogenesis in methotrexate-treated psoriatics. Acta Derm Venereol 1989; 69: 241-244.
28. Zachariae H, Aslam HM, Bjerring P et al. Serum aminoterminal propeptide of type III procollagen in psoriasis and psoriatic arthritis: relation to liver fibrosis and arthritis. J Am Acad Dermatol 1991; 25: 50-53.
29. Berends MA, Snoek J, de Jong EM et al. Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan predicts the absence of significant liver fibrosis. Liver Int 2007; 27: 639-645. (Pubitemid 47097314)
30. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-293. (Pubitemid 26260021)
31. Coton T, Matton T, Pecarrère JL et al. Interobserver reproducibility of the Knodell score and the Metavir score in chronic viral hepatitis C. Results of 60 liver biopsies. Gastroenterol Clin Biol 2001; 25: 915-916.
32. Westin J, Lagging LM, Wejstå l R et al. Interobserver study of liver histopathology using the Ishak score in patients with chronic hepatitis C virus infection. Liver 1999; 19: 183-7.